Genvoya

(Elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide)

Genvoya

Drug updated on 11/10/2023

Dosage FormTablet (oral; 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and 10 mg of tenofovir alafenamide)
Drug ClassAntivirals
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of HIV-1 infection in adults and pediatric patients weighing at least 25 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of Genvoya.